AKT1 and acute myeloid leukemia: Thus, the balance of benefit and toxicity is key to the design of clinical trials combining DDR and/or PI3K/AKT inhibitors with current AML therapies in terms of drug doses, duration of drug administration during treatment cycles, concomitant vs. sequential drug administration, and finally the length of treatment cycles.